X RX INC has a total of 29 patent applications. It increased the IP activity by 200.0%. Its first patent ever was published in 2013. It filed its patents most often in Japan, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are 4 AZA BIOSCIENCE NV, INTRA-CELLULAR THERAPIES INC and AZEVAN PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Japan | 5 | |
#2 | United States | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Australia | 2 | |
#5 | Canada | 2 | |
#6 | China | 2 | |
#7 | Hong Kong | 2 | |
#8 | Brazil | 1 | |
#9 | Chile | 1 | |
#10 | Cuba | 1 | |
#11 | Dominican Republic | 1 | |
#12 | Ecuador | 1 | |
#13 | EPO (European Patent Office) | 1 | |
#14 | Israel | 1 | |
#15 | Philippines | 1 | |
#16 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Zhang Ying | 21 |
#2 | Clark Matthew | 17 |
#3 | Keefe Anthony D | 17 |
#4 | Ni Haihong | 12 |
#5 | Wang Ce | 12 |
#6 | Xie Zhifeng | 11 |
#7 | Babiss Lee | 10 |
#8 | Renzetti Louis | 10 |
#9 | Ruebsam Frank | 10 |
#10 | Mulvihill Mark J | 9 |
Publication | Filing date | Title |
---|---|---|
JP2020007360A | Substituted n-(2-amino)-2-oxoethylbenzamide inhibitor of autotaxin and preparation thereof, and application in treatments of lpa depending or lpa mediated diseases | |
WO2020051230A1 | Amorphous pharmaceutical compositions and uses thereof | |
SG11201607920RA | Substituted spirocyclic inhibitors of autotaxin | |
EP2802324A1 | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
CN104254330A | Tryptoline derivatives having kinase inhibitory activity and uses thereof |